Park Medi World Limited ( park medi world ) will participate in three investor conferences in Mumbai during August 2026, providing analysts and institutional investors with opportunities for direct engagement with management. The company disclosed the schedule under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming that no unpublished price-sensitive information will be shared during these meetings.

The engagements are scheduled for August 12, 13, and 25, 2026. All three events will be conducted in a physical mode, allowing for both group discussions and one-on-one meetings. The conferences are organized by Emkay Global Financial Services, Equirus, and Antique Healthcare, respectively, and will take place at prominent venues in Mumbai’s business districts.

Conference Schedule

The detailed schedule for the investor interactions is as follows:

All meetings are set to begin at 10:00 a.m. local time. The company noted that the schedule is subject to change due to exigencies on the part of either the investors or the company.

Compliance and Disclosure

Abhishek Kapoor, Company Secretary & Compliance Officer of Park Medi World Limited, issued the disclosure on August 05, 2026. The announcement was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE), where the company trades under the symbol PARKHOSPS.

The disclosure emphasizes strict adherence to insider trading regulations by pre-committing that the representatives will not discuss any unpublished price-sensitive information. This standard practice ensures market integrity while allowing management to address general operational queries and strategic outlooks within public domain knowledge. The full disclosure is also available on the company’s official website.

Park Medi World Limited reported a significant improvement in profitability for the first quarter of FY27, with consolidated net profit after tax (PAT) rising 35% year-on-year to ₹885.93 million. The growth was underpinned by a 19% surge in revenue from operations, which reached ₹4,757.09 million for the quarter ended June 30, 2026, compared to ₹3,988.45 million in the corresponding period of FY26. This performance highlights the company’s ability to drive top-line growth while expanding operational margins.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 3, 2026, following recommendations from the Audit Committee. In compliance with Regulation 33 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the results in ‘The Economic Times’ and ‘Navbharat Times’ on August 4, 2026. The financial statements were subjected to a limited review by the statutory auditor, who issued unmodified reports.

Financial Performance Overview

Key financial metrics for the quarter reflect robust operational execution across the company’s network of 17 hospitals and 4,290 beds. EBITDA increased by 20% year-on-year to ₹1,260.88 million, up from ₹1,049.31 million in Q1FY26. Profit before tax also saw substantial growth, rising to ₹1,050.84 million from ₹818.99 million in the previous year’s corresponding quarter.

On a sequential basis, revenue grew marginally by 3% compared to the fourth quarter of FY26, which stood at ₹4,604.13 million. However, EBITDA declined slightly quarter-on-quarter to ₹1,260.88 million from ₹1,273.68 million in Q4FY26, indicating some pressure on operating margins despite higher revenue. Net profit, however, improved sequentially by 15% to ₹885.93 million from ₹767.78 million.

What the Numbers Show

The divergence between EBITDA and PAT trends warrants attention. While EBITDA contracted slightly on a quarterly basis, net profit expanded significantly. This suggests that non-operating factors or lower tax provisions may have contributed to the bottom-line growth in Q1FY27 relative to Q4FY26. Year-on-year, both top-line and bottom-line metrics show strong momentum, with PAT growing faster than revenue, signaling improved operational leverage over the past year. The company’s focus on consolidation and continued execution across its hospital network appears to be yielding positive financial outcomes.